Timothy Conklin works with clients in Choate’s Litigation Department.
Prior to joining Choate, Timothy was a legal intern at the U.S. Attorney’s Office for the District of Massachusetts. He also worked as a litigation paralegal, where he supported teams specializing in complex business litigation and government enforcement defense.
Publications and Presentations
- “The End of Purposeful Discrimination: The Shift to an Objective Batson Standard,” author, Boston College Law Review, March 2022.
Education & Credentials
- Boston College Law School
- JD, 2022, cum laude
- Managing Editor, Boston College Law Review
- University of Massachusetts Amherst
- BA, 2016, cum laude
National Attention for Choate’s U.S. Supreme Court Amicus Brief in Amgen v. Sanofi et al.
On March 27, the U.S. Supreme Court heard arguments in Amgen v. Sanofi et al, No. 21-757, one of this term’s most highly-watched cases concerning the law of enablement as it applies to patents directed to antibody therapeutics. Choate’s amicus brief, submitted on behalf of Nobel Prize laureate Sir Gregory Paul Winter and other interested scientists in support of Sanofi and Regeneron, was repeatedly highlighted by counsel during the argument.
Choate Submits Amicus Brief to the US Supreme Court on behalf of Nobel Laureate Sir Gregory Paul Winter and Interested Scientists in Amgen v. Sanofi et al.
On February 10, 2023, Choate submitted an amicus brief to the U.S. Supreme Court on behalf of Sir Gregory Paul Winter and other interested scientists in support of Sanofi and Regeneron in Amgen v. Sanofi et al, No. 21-757. The case involves the law of enablement for patents and whether the Federal Circuit Court of Appeals correctly interpreted the law when it invalidated Amgen’s patents directed to broad classes of antibody drugs called PCSK9 inhibitors.